Diminished airway host innate response in people with cystic fibrosis who experience frequent pulmonary exacerbations.

"Conflict of interest: During the course of the manuscript, funding for C.J. Houston's PhD studentship was received from the Department for the Economy. A. Alkhatib has no potential conflicts of interest to disclose. G.G. Einarsson reports grants from EU/EFPIA (IMI iABC grant number 115721), outside the submitted work. M.M. Tunney reports grants from Novartis, Spexis, Shionogi and NIHR EME, outside the submitted work. C.C. Taggart reports grants from Chiesi Farmaceutici, NICHS, the Medical Research Council and NIHR EME, outside the submitted work. D.G. Downey reports grants from Chiesi Farmaceutici and the CF Foundation, consulting fees from Vertex, lecture honoraria from Gilead, Chiesi, Vertex and Insmed, travel support from the European Cystic Fibrosis Society, advisory board participation with Nomab trial UK and CSL Behring, and a leadership role as Director of European CF Society Clinical Trials Network, outside the submitted work."

"Support statement: Funding was provided by the Northern Ireland Department for the Economy (DfE) (studentship to C.J. Houston). Funding information for this article has been deposited with the Crossref Funder Registry."